{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:50Z","timestamp":1793242310251,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003395","name":"Skin Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaad.2021.07.013","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T11:50:26Z","timestamp":1626263426000},"page":"1285-1292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study"],"prefix":"10.1016","volume":"86","author":[{"given":"Megan","family":"O'Donnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romsin","family":"Zaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Krishnasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyfettin Onder","family":"Alpdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2021.07.013_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jaad.2021.07.013_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4274\/tjh.2016.0502","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"35","author":"Vural","year":"2018","journal-title":"Turk J Haematol"},{"issue":"16","key":"10.1016\/j.jaad.2021.07.013_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jaad.2021.07.013_bib4","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: A retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2021.07.013_bib5","first-page":"265","article-title":"Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study","volume":"132","author":"Salhany","year":"1988","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.jaad.2021.07.013_bib6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1987.5.2.208","article-title":"Cytologic transformation in cutaneous T cell lymphoma: A clinicopathologic entity associated with poor prognosis","volume":"5","author":"Dmitrovsky","year":"1987","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2021.07.013_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hon.2900080406","article-title":"Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process","volume":"8","author":"Greer","year":"1990","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2021.07.013_bib8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jaad.2021.07.013_bib9","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of cutaneious Lymphomas","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2021.07.013_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2007.08008.x","article-title":"Transformed mycosis fungoides: clinicopathological features and outcome","volume":"157","author":"Barberio","year":"2007","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.07.013_bib11","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.jaad.2021.07.013_bib12","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2021.07.013_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaad.2011.12.011","article-title":"Recognizing large-cell transformation of mycosis fungoides","volume":"67","author":"Herrmann","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.07.013_bib14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"issue":"9","key":"10.1016\/j.jaad.2021.07.013_bib15","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1111\/ijd.12875","article-title":"Correlations between clinical and pathological features in 17 cases of mycosis fungoides before and after transformation","volume":"54","author":"Bittencourt","year":"2015","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.07.013_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cup.13375","article-title":"Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation","volume":"46","author":"Raghavan","year":"2019","journal-title":"J Cutan Pathol"},{"issue":"7","key":"10.1016\/j.jaad.2021.07.013_bib17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pathol.2018.08.008","article-title":"Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression","volume":"50","author":"Wang","year":"2018","journal-title":"Pathology"},{"issue":"8","key":"10.1016\/j.jaad.2021.07.013_bib18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/jdv.15526","article-title":"Epidemiology and prognostic factors for mycosis fungoides and Sezary syndrome in a multi-ethnic Asian cohort: A 12-year review","volume":"33","author":"Lim","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.07.013_bib19","first-page":"153","article-title":"Mycosis fungoides: A 10-year Turkish experience","volume":"27","author":"Baykal Selcuk","year":"2019","journal-title":"Acta Dermatovenerol Croat"},{"issue":"9","key":"10.1016\/j.jaad.2021.07.013_bib20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jaad.2021.07.013_bib21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.clml.2020.05.001","article-title":"Outcomes of patients with transformed mycosis fungoides: analysis from a prospective multicenter US cohort Study","volume":"20","author":"Lansigan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10094","key":"10.1016\/j.jaad.2021.07.013_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2021.07.013_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to Brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.jaad.2021.07.013_bib24","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2021.07.013_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2014.1629","article-title":"Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome","volume":"151","author":"Mehra","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"32","key":"10.1016\/j.jaad.2021.07.013_bib26","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of Brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.jaad.2021.07.013_bib27","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: A multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2021.07.013_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamadermatol.2017.3961","article-title":"Treatment of CD30-negative refractory mycosis fungoides with brentuximab vedotin","volume":"154","author":"Zhang","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.07.013_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/cup.13140","article-title":"Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin","volume":"45","author":"Pham","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"6","key":"10.1016\/j.jaad.2021.07.013_bib30","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/bjd.17254","article-title":"Dramatic response to brentuximab vedotin in refractory nontransformed CD30- mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission","volume":"180","author":"Mahevas","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.07.013_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bjd.18535","article-title":"Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma","volume":"182","author":"Engelina","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.07.013_bib32","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.18806","article-title":"Effectiveness of Brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides","volume":"182","author":"Andre","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222102106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222102106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:57Z","timestamp":1759273317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222102106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S019096222102106X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.07.013","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}